Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab for prevention of attacks in non-histaminergic angioedema with normal C1 inhibitor
NL-OMON55293Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanadelumab in angioedema, sponsored by Takeda. Primary endpoint: Number of investigator-confirmed angioedema attacks during the treatment period. Started May 2021; status: active, not recruiting.
02
Drugs
lanadelumab
03
Conditions
angioedema
Beyond the preview
Go deeper on NL-OMON55293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55293.